Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Remme

Showing results (211-220 of 236) with videos related to

Pageof 24
Sort By:
European Heart Journal|July 26, 2005
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trialMarco Metra, Christian Torp-Pedersen, Karl Swedberg, et al.
Lancet (London, England)|July 11, 2003
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialPhilip A Poole-Wilson, Karl Swedberg, John G F Cleland, et al.
International Journal of Cardiology|January 12, 2015
Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPAJoep van der Leeuw, Rohit M Oemrawsingh, Yolanda van der Graaf, et al.
European Heart Journal|September 2, 2005
Public awareness of heart failure in Europe: first results from SHAPEWillem J Remme, John J V McMurray, Bernhard Rauch, et al.
Annals of Tropical Medicine and Parasitology|January 23, 2003
The use of spatial analysis in mapping the distribution of bancroftian filariasis in four West African countriesJ O Gyapong, D Kyelem, I Kleinschmidt, et al.
Hypertension (Dallas, Tex. : 1979)|July 14, 2010
Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trialsKaty J L Bell, Andrew Hayen, Petra Macaskill, et al.
Cardiovascular Drugs and Therapy|February 3, 2011
Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II)Siobhan Gallanagh, Davide Castagno, Ben Wilson, et al.
European Journal of Heart Failure|April 1, 2010
Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trialDavide Castagno, Pardeep S Jhund, John J V McMurray, et al.
Journal of the American Heart Association|March 30, 2016
Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk ModelRohit M Oemrawsingh, K Martijn Akkerhuis, Laura C Van Vark, et al.
European Heart Journal|May 20, 2005
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of CardiologyKarl Swedberg, John Cleland, Henry Dargie, et al.
Pageof 24

Showing results (211-220 of 236) with videos related to

Sort By:
Pageof 24
European Heart Journal|July 26, 2005
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trialMarco Metra, Christian Torp-Pedersen, Karl Swedberg, et al.
Lancet (London, England)|July 11, 2003
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialPhilip A Poole-Wilson, Karl Swedberg, John G F Cleland, et al.
International Journal of Cardiology|January 12, 2015
Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPAJoep van der Leeuw, Rohit M Oemrawsingh, Yolanda van der Graaf, et al.
European Heart Journal|September 2, 2005
Public awareness of heart failure in Europe: first results from SHAPEWillem J Remme, John J V McMurray, Bernhard Rauch, et al.
Annals of Tropical Medicine and Parasitology|January 23, 2003
The use of spatial analysis in mapping the distribution of bancroftian filariasis in four West African countriesJ O Gyapong, D Kyelem, I Kleinschmidt, et al.
Hypertension (Dallas, Tex. : 1979)|July 14, 2010
Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trialsKaty J L Bell, Andrew Hayen, Petra Macaskill, et al.
Cardiovascular Drugs and Therapy|February 3, 2011
Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II)Siobhan Gallanagh, Davide Castagno, Ben Wilson, et al.
European Journal of Heart Failure|April 1, 2010
Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trialDavide Castagno, Pardeep S Jhund, John J V McMurray, et al.
Journal of the American Heart Association|March 30, 2016
Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk ModelRohit M Oemrawsingh, K Martijn Akkerhuis, Laura C Van Vark, et al.
European Heart Journal|May 20, 2005
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of CardiologyKarl Swedberg, John Cleland, Henry Dargie, et al.
Pageof 24